Promising drug expected to become the first to slow down dementia found to not work US pharma giant Eli Lilly announced a trial of 2,000 people had shown solanezumab showed no benefit for people with mild Alzheimer's, causing their share prices to take a tumble.
The Daily Mail
No comments:
Post a Comment